2 408

Cited 7 times in

A phase II feasibility study of weekly paclitaxel in heavily pretreated advanced gastric cancer patients with poor performance status

Authors
 Chong Kun Im  ;  Sun Young Rha  ;  Hei-Cheul Jeung  ;  Jaeheon Jeong  ;  Soo Hyeon Lee  ;  Sung Hoon Noh  ;  Jae Kyung Roh  ;  Hyun Cheol Chung 
Citation
 ONCOLOGY, Vol.77(6) : 349-357, 2009 
Journal Title
ONCOLOGY
ISSN
 0030-2414 
Issue Date
2009
MeSH
Adult ; Aged ; Antineoplastic Agents, Phytogenic/therapeutic use* ; FeasibilityStudies ; Female ; Humans ; Male ; Middle Aged ; Paclitaxel/adverse effects ; Paclitaxel/therapeutic use* ; Prognosis ; Stomach Neoplasms/drug therapy* ; Stomach Neoplasms/mortality
Keywords
Advanced gastric cancer ; Paclitaxel monotherapy ; Poor performance status ; Weekly paclitaxel
Abstract
PURPOSE: We investigated the efficacy and safety of weekly paclitaxel monotherapy in previously treated patients with advanced gastric cancer (AGC) and poor performance status (PS) according to the Eastern Cooperative Oncology Group (ECOG). PATIENTS AND METHODS: Patients with evaluable disease who failed at least one previous chemotherapy and had a PS of 2-3, received paclitaxel 70 mg/m(2) on days 1, 8 and 15 every 4 weeks. RESULTS: The median overall survival (OS) was 5.5 months (95% confidence interval, CI, 3.3-7.8) and progression-free survival was 2.1 months (95% CI, 1.2-3.0). The overall response rate was 3.8% and the disease control rate was 25.0%. Treatment-related toxicities were tolerable. OS was 7.1 (95% CI, 5.4-9.5) and 3.7 months (95% CI, 2.1-5.3) for patients with PS-ECOG 2 and 3, respectively (p < 0.001). When evaluated according to the previous treatment, OS was 5.1 (95% CI, 3.3-7.0) and 6.5 months (95% CI, 3.8-9.3) for patients receiving two and three or more lines of treatment, respectively (p = 0.815). With multivariate analysis, PS was a significant factor for OS. CONCLUSION: Survival in patients treated with weekly paclitaxel monotherapy was comparable to other second- or third-line chemotherapies for AGC, with acceptable toxicities in previously treated patients with poor PS.
Full Text
http://www.karger.com/Article/FullText/265941
DOI
10.1159/000265941
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Noh, Sung Hoon(노성훈) ORCID logo https://orcid.org/0000-0003-4386-6886
Roh, Jae Kyung(노재경)
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
Lee, Soo Hyeon(이수현)
Jung, Jae Hun(정재헌)
Chung, Hyun Cheol(정현철) ORCID logo https://orcid.org/0000-0002-0920-9471
Jeung, Hei Cheul(정희철) ORCID logo https://orcid.org/0000-0003-0952-3679
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/105538
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links